(PDF) Psy169 - Comparison of Eu5 Market Access Decisions

Psy169 - Comparison of Eu5 Market Access Decisions for Crohn’s Disease Based on the Prismaccess® Database

Value in Health - United Kingdom

doi 10.1016/j.jval.2018.09.2743

Full Text

Abstract

Available in full text

Categories

Occupational Health

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

Php230 - Eu5 Market Access for Medicines Approved Under Exceptional Circumstances

Value in Health

Occupational Health

English

Php229 - Eu5 Market Access for Medicines With Conditional Marketing Authorisations

Value in Health

Occupational Health

English

Pcn292 - Cancer Drugs in Germany: Hta Decisions of New and Innovative Oncology Drugs in Germany – An Analysis Using the Prismaccess® Database

Value in Health

Occupational Health

English

Pmd168 - Market Access for Companion Diagnostics in Oncology in the Eu5 and Asia-Pacific Region

Value in Health

Occupational Health

English

Php217 - Time to Market and Price Comparison for Biosimilar Drugs in Eu5

Value in Health

Occupational Health

English

Pnd92 - Access and Reimbursement for Current and Emerging Alzheimer’s Disease-Modifying Therapies in the Eu5

Value in Health

Occupational Health

English

Reducing Consumption Versus Maintaining Abstinence: Market Access Challenges Facing a Novel Treatment Pathway for Alcohol Addiction in the Eu5

Value in Health

Occupational Health

English

Application of the Montreal Classification for Crohn’s Disease to a Single Clinician Database of 1015 Patients

Canadian Journal of Gastroenterology

English

Market Access Risk Scoring: A Unified Framework for Cross Country Comparison of Diverse Market Access Systems and Processes

Value in Health

Occupational Health

English